Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene

Pharmacogenetics and Genomics

Volumn 20, Issue 11, 2010, Pages 700-707

  Appell, Malin Lindqvist ^a   Wennerstrand, Patricia ^b   Peterson, Curt ^a   Hertervig, Erik ^c   Mårtensson, Lars Göran ^b  

^a Faculty of Health Sciences   (Australia)

^b LINKÖPING UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

pharmacogenetics; protein stability; right angle light scattering; single nucleotide polymorphism; thiopurine methyltransferase

Indexed keywords

AZATHIOPRINE; ISOLEUCINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE 28; THREONINE; TIOGUANINE; UNCLASSIFIED DRUG;

AGED; ALPHA HELIX; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CASE REPORT; DNA SEQUENCE; ENZYME ACTIVITY; EXON; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ESCHERICHIA COLI;

EID: 78049296472     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283402ee4     Document Type: Article

References (26)

1. Woodson LC, Weinshilboum RM. Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol 1983; 32:819-826.
2. Remy CN. Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem 1963; 238:1078-1084.
3. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43:329-339.
4. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273:1109-1111.
5. Coulthard SA, Hogarth LA, Little M, Matheson EC, Redfern CP, Minto L, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol 2002; 62:102-109.
6. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001; 61:5810-5816.
7. Weinshilboum R, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662.
8. Pettersson B, Almer S, Albertioni F, Söderhall S, Peterson C. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 2002; 24:351-358.
9. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126:608-614.
10. Fotoohi AK, Coulthard SA, Albertioni F. Thiopurines: factors influencing toxicity and response. Biochem Pharmacol 2010; 79:1211-1220.
11. Feng Q, Vannaprasaht S, Peng Y, Angsuthum S, Avihingsanon Y, Yee VC, et al. Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. Biochem Pharmacol 2009; 79:1053-1061.
12. Lindqvist M, Haglund S, Almer S, Peterson C, Taipalensu J, Hertervig E, et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics 2004; 14:261-265.
13. Lindqvist M, Skoglund K, Karlgren A, Soderkvist P, Peterson C, Kidhall I, et al. Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23. Pharmacogenet Genomics 2007; 17:891-895.
14. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci \USA 2005; 102:9394-9399.
15. Wu H, Horton JR, Battaile K, Allali-Hassani A, Martin F, Zeng H, et al. Structural basis of allele variation of human thiopurine-S-methyltransferase. Proteins 2007; 67:198-208.
16. Rutherford K, Daggett V. Four human thiopurine s-methyltransferase alleles severely affect protein structure and dynamics. J Mol Biol 2008; 379:803-814.
17. Peng Y, Feng Q, Wilk D, Adjei AA, Salavaggione OE, Weinshilboum RM, et al. Structural basis of substrate recognition in thiopurine S-methyltransferase. Biochemistry 2008; 47:6216-6225.
18. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279-290.
19. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1983; 16:359-363.
20. Ford L, Prout C, Gaffney D, Berg J. Whose TPMT activity is it anyway? Ann Clin Biochem 2004; 41:498-500.
21. Yan L, Zhang S, Eiff B, Szumlanski CL, Powers M, O'Brien JF, et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000; 68:210-219.
22. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003; 31:3812-3814.
23. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30:3894-3900.
24. Berman HM. The Protein Data Bank: a historical perspective. Acta Crystallogr A 2008; 64:88-95.
25. Tai HL, Fessing MY, Bonten EJ, Yanishevsky Y, D'Azzo A, Krynetski EY, et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999; 9:641-650.
26. Kham SK, Soh CK, Aw DC, Yeoh AE. TPMT*26 (208F-> L): a novel mutation detected in a Chinese. Br J Clin Pharmacol 2009; 68:120-123.